Clinical Research Directory

Inclusion Criteria: * Adult infection episodes among patients aged 20 years or older. * Confirmed acute SARS-CoV-2 positivity recorded in the Infectious Disease Information System (ISIN) during the Omicron-era study period. * Eligible for analysis at time zero, defined as the date of molnupiravir dispensing for treated patients and the matched date for controls. * Mild-to-moderate COVID-19 suitable for oral antiviral treatment, operationalized by excluding those already dead, in ICU, or receiving mechanical ventilation at time zero. Exclusion Criteria: * Age below 20 years at time of positivity. * Death, ICU hospitalization, or mechanical ventilation at time zero. * Receipt of molnupiravir, monoclonal antibodies, remdesivir, or nirmatrelvir/ritonavir within 14 days before positivity. * Receipt of molnupiravir, monoclonal antibodies, remdesivir, or nirmatrelvir/ritonavir within 14 days after the qualifying SARS-CoV-2 positivity, but outside the treatment-initiation eligibility window according to the SmPC.